TY - JOUR
T1 - Mild cognitive impairment in older adults
AU - Geda, Yonas E.
N1 - Funding Information:
Acknowledgments I would like to thank Ronald C. Petersen, MD, PhD, and all other members of Mayo Clinic Study of Aging and Mayo Alzheimer's Center for their consistent and undying support. Additionally, I would like to thank Barbara J. Balgaard for her superb secretarial assistance. Preparation of this article was supported by K01 MH68351, U01 AG06786, P50 AG16574, and RR024150 from the National Institutes of Health and the Robert Wood Johnson Foundation.
PY - 2012/8
Y1 - 2012/8
N2 - Mild cognitive impairment (MCI) is the intermediate stage between the cognitive changes of normal aging and dementia. MCI is important because it constitutes a high risk group for dementia. Ideally, prevention strategies should target individuals who are not even symptomatic. Indeed, the field is now moving towards identification of asymptomatic individuals who have underlying Alzheimer's disease (AD) pathology that can be detected using biomarkers and neuroimaging technologies. To this effect, the Alzheimer's Association and the National Institute on Aging have developed a new classification scheme that has categorized AD into a preclinical phase (research category), MCI due to AD, and dementia of Alzheimer's type. However, there are also ongoing research studies to understand high-risk groups for non-Alzheimer's dementia.
AB - Mild cognitive impairment (MCI) is the intermediate stage between the cognitive changes of normal aging and dementia. MCI is important because it constitutes a high risk group for dementia. Ideally, prevention strategies should target individuals who are not even symptomatic. Indeed, the field is now moving towards identification of asymptomatic individuals who have underlying Alzheimer's disease (AD) pathology that can be detected using biomarkers and neuroimaging technologies. To this effect, the Alzheimer's Association and the National Institute on Aging have developed a new classification scheme that has categorized AD into a preclinical phase (research category), MCI due to AD, and dementia of Alzheimer's type. However, there are also ongoing research studies to understand high-risk groups for non-Alzheimer's dementia.
KW - Age-associated cognitive decline
KW - Age-associated memory impairment
KW - Aging
KW - Asymptomatic Alzheimer's disease
KW - Benign and malignant forgetfulness
KW - Cognitive impairment no dementia
KW - Dementia
KW - Dementia of Alzheimer's type
KW - Mild cognitive impairment
KW - Mild neurocognitive decline
KW - Neuropsychiatric symptoms
KW - Questionable dementia
UR - http://www.scopus.com/inward/record.url?scp=84865660409&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84865660409&partnerID=8YFLogxK
U2 - 10.1007/s11920-012-0291-x
DO - 10.1007/s11920-012-0291-x
M3 - Article
C2 - 22773365
AN - SCOPUS:84865660409
SN - 1523-3812
VL - 14
SP - 320
EP - 327
JO - Current Psychiatry Reports
JF - Current Psychiatry Reports
IS - 4
ER -